Notice of 2026 second extraordinary general meeting
Filed with HKEX · Stock code 6872 · · 2 pages · English
Summary by 6ix AI
This filing is a notice for the second extraordinary general meeting of TenNor Therapeutics (Suzhou) Limited scheduled for a future date. The notice outlines several resolutions to be considered, including the approval of a share award scheme and amendments to the Articles of Association. Shareholders are informed about the voting process and requirements for attending the meeting. The document also includes details about proxy appointments and the closure of the H Share register for determining voting eligibility.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
TenNor Therapeutics Suzhou Ltd. on 6ix
Earlier from TenNor Therapeutics Suzhou
- Circular of 2026 second extraordinary general meeting
- 2026 Interim report
- Formulation of the 2026 h share award scheme; and (2) amendments to the articles of association
- Poll results of the annual shareholders' meeting held on Monday, June 29, 2026
Later from TenNor Therapeutics Suzhou
- Form of proxy for 2026 second extraordinary general meeting to be held on October 23, 2026
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Voluntary announcement completion of enrollment of the first patient in the multi-center Phase IIb clinical trial of rifaquizinone (TNP-2092) administered via intra-articular injection for the treatment of prosthetic joint infection
- Poll results of the 2026 second extraordinary general meeting held on Friday, October 23, 2026 and amendments to the articles of association
- Articles of Association
Follow TenNor Therapeutics Suzhou into a list and get an email when it puts out news.
Follow TenNor Therapeutics Suzhou